BioCentury
ARTICLE | Company News

Lilly bolsters atopic dermatitis arsenal via $1.1B Dermira deal, gaining Dupixent challenger

January 10, 2020 6:44 PM UTC
Updated on Jan 11, 2020 at 12:15 AM UTC

Via its $1.1 billion takeout of Dermira on Friday, Eli Lilly added to its late-stage pipeline an atopic dermatitis therapy that could challenge Dupixent.

The price -- $18.75 per share -- is a premium of only 2% to Thursday’s close of $18.34, but the deal comes during a week when Dermira Inc. (NASDAQ:DERM) shares added $200 million in market cap on heavy volume. The price is a 50% premium to Dermira’s intraday low of $12.50 on Monday, and an 86% premium to Dermira’s last 60-day volume-weighted average price...

BCIQ Company Profiles

Dermira Inc.

Eli Lilly and Co.